XNAS · Healthcare · Biotechnology
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | 0.39 | 0.52 | +33.33% | $132.9M | ✅ Beat | +2.36% | +7.23% | — |
| 2026-03-05 | Q4 2025 | 0.33 | 0.15 | -54.55% | $92.0M | ❌ Miss | -1.11% | +8.86% | +9.15% |
| 2025-11-03 |
| Q3 2025 |
| -0.38 |
| -0.04 |
| +89.47% |
| $54.3M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.41 | -0.49 | -19.51% | $8.8M | ❌ Miss | +0.00% | +12.49% | +12.03% |
| 2025-05-08 | Q1 2025 | -0.42 | -0.45 | -7.14% | $3.1M | ❌ Miss | — | — | — |
| 2025-03-19 | Q4 2024 | -0.40 | -0.46 | -15.00% | $2.9M | ❌ Miss | — | — | — |
| 2024-11-13 | Q3 2024 | -0.37 | -0.39 | -5.41% | $4.4M | ❌ Miss | — | — | — |
| 2024-08-07 | Q2 2024 | -0.34 | -0.37 | -8.82% | $3.7M | ❌ Miss | — | — | — |
Showing last 8 quarters.